New gastroenterology study

10 August 2007

OCT announces opening of the sites in Russia within the framework of the gastroenterological clinical study on the irritable bowel syndrome for Menarini.

OCT Vision

“OCT vision is to be recognized by pharmaceutical and biotech companies as a leading provider of clinical trials in Russia, Ukraine, Bulgaria, Belarus, Latvia, Lithuania, Estonia, Poland and Czech Republic. OCT is able to support any requirements that clients may have in the region, ranging from one-off advice to full-study implementation and execution. We are determined and decisive in expanding our activity at this rapidly growing market”— Dmitry Sharov, General Manager of OCT.